Summary
• Myomo Inc. (MYO) shares increased 5% in pre-market, reaching $0.8800 due to recent insider purchases.
• Directors Kirk Thomas F and Crowley Thomas Aloysius Jr. acquired a combined total of over 7,000 shares, indicating insider confidence.
• Despite recent earnings surpassing expectations, MYO shares are down approximately 87% year-to-date, highlighting market volatility.
Myomo Inc. (MYO) is showing a notable pre-market increase of 5% as shares reach $0.8800, up from the last closing price of $0.8379. This move highlights a growing interest among investors, coinciding with recent insider transactions suggesting potential confidence in the company’s direction.
Insider Transactions Signal Confidence
Recently, director Kirk Thomas F made multiple stock purchases, acquiring 2,535 shares at $0.72 each and 4,902 shares at the same price over two days. In total, his purchases amount to approximately $5,354. Additionally, director Crowley Thomas Aloysius Jr. purchased 4,000 shares at $0.7345, alongside a smaller acquisition of 385 shares at $0.765. These transactions come as Myomo reported strong financial results in their last earnings announcement, illustrating a strategic commitment from the company’s leadership.
Financial and Operational Highlights
Myomo’s third-quarter earnings report noted that revenues came in at the high end of expectations, driven by record levels in both U.S. and international orthotics and prosthetics (O&P) revenues. The company achieved an actual loss per share of $0.08686, beating analyst estimates predicting a larger loss of $0.11. This surprise reflects a growing operational efficiency amid challenging market conditions.
Despite these positive movements, year-to-date performance remains concerning, with shares down approximately 87%. The average trading volume over the last three months stands at 1,533,999 shares, reinforcing the stock’s liquidity but highlighting volatility.
Market and Technical Commentary
The stock’s 20-day simple moving average (SMA) indicates a strong divergence, with current levels distinctly high compared to the negative positioning of the 50-day and 200-day SMAs at -10.99% and -68.76%, respectively. As of now, Myomo’s RSI sits at 46.42, suggesting it is nearing the neutral zone and may warrant close attention from traders typically monitoring momentum shifts. The stock’s weekly performance has taken a hit, reflecting a decline of 7.81% recently but reveals opportunities for potential rebound amid new interest.
Analyst Sentiment
According to available data, Myomo maintains a “Buy” rating from Ascendiant Capital, with adjusted price targets reflecting broader market appreciation for the company’s prospects in wearable medical technology. Analyst Edward Woo recently reiterated this stance, keeping the price target firmly set between $10 and $10.50.
With the latest insider actions now reflected in trading, investors will be monitoring how the stock’s volume and momentum develop in the next session.